Axon Enterprise (NASDAQ:AXON) Coverage Initiated at TD Cowen

Research analysts at TD Cowen started coverage on shares of Axon Enterprise (NASDAQ:AXON) in a report issued on Wednesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $700.00 price target on the biotechnology company’s stock. TD Cowen’s price target would indicate a potential upside of 24.55% from the company’s current price.

A number of other research analysts have also weighed in on AXON. Northland Securities raised their target price on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a report on Monday, November 11th. The Goldman Sachs Group raised their price objective on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Robert W. Baird upped their target price on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. Finally, Needham & Company LLC upped their price objective on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $504.92.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $562.03 on Wednesday. The stock has a market cap of $42.86 billion, a price-to-earnings ratio of 145.23, a PEG ratio of 14.19 and a beta of 1.04. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise has a fifty-two week low of $244.01 and a fifty-two week high of $698.67. The firm’s 50-day simple moving average is $598.56 and its 200 day simple moving average is $445.07.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the transaction, the director now owns 6,929 shares in the company, valued at $4,185,601.03. This trade represents a 6.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Garnreiter sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the completion of the sale, the director now directly owns 26,259 shares in the company, valued at approximately $11,500,916.82. This trade represents a 3.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,545 shares of company stock worth $31,159,317 over the last ninety days. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Groupama Asset Managment purchased a new position in shares of Axon Enterprise in the third quarter valued at $200,000. Massachusetts Financial Services Co. MA bought a new position in Axon Enterprise in the 3rd quarter worth about $120,553,000. International Assets Investment Management LLC purchased a new position in Axon Enterprise during the 3rd quarter valued at about $871,860,000. Westfield Capital Management Co. LP increased its position in shares of Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock valued at $469,661,000 after buying an additional 127,769 shares during the period. Finally, 1832 Asset Management L.P. lifted its holdings in shares of Axon Enterprise by 44.0% in the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after buying an additional 114,800 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.